[HTML][HTML] Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation

SH Chen, KB Pham-Nguyen, O Martinet, Y Huang… - Molecular Therapy, 2000 - cell.com
SH Chen, KB Pham-Nguyen, O Martinet, Y Huang, W Yang, SN Thung, L Chen, R Mittler…
Molecular Therapy, 2000cell.com
In an orthotopic model of metastatic colon carcinoma established in the liver of mice, we
have previously shown that the natural killer (NK) cells were the major effectors after
intratumoral delivery of a recombinant adenovirus expressing the murine IL-12 gene.
However, tumor cure and long-term survival were achieved only in a minority of animals. In
the present study, we generated an effective antitumoral CD8+ T-cell response by the
combination of IL-12 gene therapy and systemic delivery of an agonistic monoclonal …
In an orthotopic model of metastatic colon carcinoma established in the liver of mice, we have previously shown that the natural killer (NK) cells were the major effectors after intratumoral delivery of a recombinant adenovirus expressing the murine IL-12 gene. However, tumor cure and long-term survival were achieved only in a minority of animals. In the present study, we generated an effective antitumoral CD8+ T-cell response by the combination of IL-12 gene therapy and systemic delivery of an agonistic monoclonal antibody against 4-1BB, a costimulatory molecule expressed on activated T cells. In the IL-12 plus anti-4-1BB combination treatment, the effective dose of IL-12 could even be reduced even up to 18-fold and still achieved a better efficacy than the maximal dose of either treatment alone. We further demonstrate that the innate and the adaptive antitumoral immune responses were synergistic, as animals bearing hepatic as well as multiple pulmonary metastases were quantitatively cured of their diseases after IL-12 gene therapy + anti-4-1BB combination treatment. Both NK and CD8+ T cells were necessary in maintaining the long-term antitumor immunity, as depletion of either cell type in the cured animals abolished their abilities to reject tumor cells implanted at distal sites. These results indicate that synergism between innate and adaptive immune responses may be effectively exploited to treat patients with metastatic diseases.
cell.com